New European approval: Duvelisib  - relapsed/refractory CLL and follicular lymphoma

Bull Cancer. 2021 Oct 1:S0007-4551(21)00309-X. doi: 10.1016/j.bulcan.2021.06.010. Online ahead of print.NO ABSTRACTPMID:34607678 | DOI:10.1016/j.bulcan.2021.06.010
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research